Overcoming Resistance to EGFR Inhibitors in EGFR Mutant NSCLC

Book Overcoming Resistance to EGFR Inhibitors in EGFR Mutant NSCLC Cover

Read or download book entitled Overcoming Resistance to EGFR Inhibitors in EGFR Mutant NSCLC written by Anthony Faber and published by Academic Press in PDF, EPUB and Kindle Format. Click Get This Book button to download or read online books. Join over 650.000 happy Readers and READ as many books as you like. We cannot guarantee that Overcoming Resistance to EGFR Inhibitors in EGFR Mutant NSCLC book is available in the library.

  • Publisher : Academic Press
  • Release : 15 March 2021
  • ISBN : 0128228334
  • Page : 250 pages
  • Rating : 4.5/5 from 103 voters

Download Overcoming Resistance to EGFR Inhibitors in EGFR Mutant NSCLC in PDF, Epub and Kindle

Overcoming Resistance to EGFR Inhibitors in EGFR Mutant NSCLC, Volume 17 presents updated information on how EGFR mutant lung cancers evolve to evade EGFR inhibitors, clinical strategies that identify these mechanisms, and how to implement newer therapeutic strategies to combat resistance and improve patient survival. As resistance to EGFR inhibitors is often through re-activation of MEK/ERK and PI3K pathways, or through loss of cell death responses, there is much overlap with resistance to targeted therapies in other paradigms, such as BRAF inhibitors in BRAF mutant melanoma, and HER2 inhibitors in HER2 amplified breast cancer. This book is a valuable resource for cancer researchers, clinicians, graduate students and other members of the biomedical field who are interested in promising treatments for lung cancer. Presents historical context on how NSCLC and SCLC has been treated, with an emphasis on NSCLC and how the concept of EGFR inhibitors has been implemented Discusses critical resistant mechanisms seen in the clinic to 1st, 2nd and 3rd generation EGFR inhibitors Encompasses the current state of affairs in clinical trials to address resistance

GET THIS BOOK

Overcoming Resistance to EGFR Inhibitors in EGFR Mutant NSCLC

Overcoming Resistance to EGFR Inhibitors in EGFR Mutant NSCLC
  • Author : Anthony Faber
  • Publisher : Academic Press
  • Release Date : 2021-03-15
  • ISBN : 0128228334
GET THIS BOOKOvercoming Resistance to EGFR Inhibitors in EGFR Mutant NSCLC

Overcoming Resistance to EGFR Inhibitors in EGFR Mutant NSCLC, Volume 17 presents updated information on how EGFR mutant lung cancers evolve to evade EGFR inhibitors, clinical strategies that identify these mechanisms, and how to implement newer therapeutic strategies to combat resistance and improve patient survival. As resistance to EGFR inhibitors is often through re-activation of MEK/ERK and PI3K pathways, or through loss of cell death responses, there is much overlap with resistance to targeted therapies in other paradigms, such

Overcoming Drug Resistance in Gynecologic Cancers

Overcoming Drug Resistance in Gynecologic Cancers
  • Author : Anonim
  • Publisher : Academic Press
  • Release Date : 2021-08-11
  • ISBN : 9780128243008
GET THIS BOOKOvercoming Drug Resistance in Gynecologic Cancers

Overcoming Drug Resistance in Gynecologic Cancers provides up-to-date information related to important gynecologic cancers and focuses on mechanisms of drug resistance, genetics, signaling, immunology, health disparities, nanotechnology, economic considerations and financial impacts. The book covers not only drug resistance but also important means to reverse resistance both in the laboratory and clinic. The book discusses topics such as lifestyle, nutrition and risk of gynecologic cancers, the financial impact of drug resistance, chemosensitizing agents and targeted therapies in cervical, endometrial and

Epigenetic Regulation in Overcoming Chemoresistance

Epigenetic Regulation in Overcoming Chemoresistance
  • Author : Chunfu Wu,Lihui Wang
  • Publisher : Academic Press
  • Release Date : 2021-06-26
  • ISBN : 9780128236857
GET THIS BOOKEpigenetic Regulation in Overcoming Chemoresistance

Epigenetic Regulation in Overcoming Chemoresistance, Volume 19, explains how epigenetic agents can enhance the chemotherapy sensitivity of diverse types of cancers. The book provides a comprehensive delineation and the recent development of the scientific studies on the epigenetic regulation in enhancing chemo-sensitivity. In addition, it discusses several topics such as DNA methyltransferase inhibitors (DNMTi), Histone deacetylases inhibitors (HDACi), Histone lysine demethylases inhibitors (HDMi), Histone lysine methyltransferases inhibitors (HMTi) and drugs regulating the microRNA, long non-coding RNA (lncRNA) or RNA methylation. Finally,

Third-Generation EGFR Inhibitors

Third-Generation EGFR Inhibitors
  • Author : Harun M. Patel,Rahul Pawara,S. J. Surana
  • Publisher : Elsevier
  • Release Date : 2019-03-15
  • ISBN : 0081026617
GET THIS BOOKThird-Generation EGFR Inhibitors

EGFR inhibitors are useful tools in cancer therapeutics, but resistance to the first generations have significantly increased, meaning a new generation of improved inhibitors are needed with better efficacy and lower toxicity. Third Generation EGFR Inhibitors: Overcoming EGFR Resistance and Toxicity Problems reviews current issues relating to the design of reversible and irreversible third generation EGFR inhibitors, highlighting the types of mutation responsible for resistance, and providing different chemical starting points for researchers to optimize and develop in designing the

Glioblastoma Resistance to Chemotherapy: Molecular Mechanisms and Innovative Reversal Strategies

Glioblastoma Resistance to Chemotherapy: Molecular Mechanisms and Innovative Reversal Strategies
  • Author : Ramasamy Paulmurugan,Tarik F. Massoud
  • Publisher : Academic Press
  • Release Date : 2021-06-25
  • ISBN : 9780128215685
GET THIS BOOKGlioblastoma Resistance to Chemotherapy: Molecular Mechanisms and Innovative Reversal Strategies

Glioblastoma Resistance to Chemotherapy: Molecular Mechanisms and Innovative Reversal Strategies brings current knowledge from an international team of experts on the science and clinical management of glioblastoma chemoresistance. The book discusses topics such as molecular mechanisms of chemoresistance, experimental models to study chemoresistance, chemoresistance to drugs other than Temozolomide, and specific strategies to reverse chemoresistance. Additionally, it encompasses information on how to mitigate chemoresistance by targeted enhancement of p53 function. This book is a valuable resource for cancer researchers, oncologists,

Current Applications for Overcoming Resistance to Targeted Therapies

Current Applications for Overcoming Resistance to Targeted Therapies
  • Author : Myron R. Szewczuk,Bessi Qorri,Manpreet Sambi
  • Publisher : Springer
  • Release Date : 2019-07-15
  • ISBN : 9783030214777
GET THIS BOOKCurrent Applications for Overcoming Resistance to Targeted Therapies

Targeted therapies were initially developed to exploit the upregulation and dependence on key oncogenic pathways critical to cancer progression. Additionally, they also presented as a method to overcome chemoresistance by supplementing conventional therapeutic regimens with targeted therapies. However, the development of resistance to these combinatorial approaches has led to the reassessment of currently available therapeutic options to overcome resistance to targeted therapy. This book aims to provide an update on the advancements in the therapeutic arms race between cancer, clinicians

Acquired Resistance to Targeted Therapy in EGFR-mutant Lung Adenocarcinoma

Acquired Resistance to Targeted Therapy in EGFR-mutant Lung Adenocarcinoma
  • Author : Caroline Amalia Nebhan
  • Publisher : Unknown
  • Release Date : 2014
  • ISBN : OCLC:890391699
GET THIS BOOKAcquired Resistance to Targeted Therapy in EGFR-mutant Lung Adenocarcinoma

Antiangiogenic Drugs as Chemosensitizers in Cancer Therapy

Antiangiogenic Drugs as Chemosensitizers in Cancer Therapy
  • Author : Anonim
  • Publisher : Academic Press
  • Release Date : 2022-01-14
  • ISBN : 9780323905565
GET THIS BOOKAntiangiogenic Drugs as Chemosensitizers in Cancer Therapy

Anti-angiogenic Drugs as Chemosensitizers in Cancer Therapy, Volume 19 focuses on the use of anti-angiogenic drugs as sensitizers of tumor cells to the inhibitory activity of antitumor agents. Conventional and novel anti-neoplastic agents (cytotoxic molecules, hormones/antihormones, immunotherapies) are taken into consideration, along with advances made in combination therapies. The book encompasses examples of studies on the use of antiangiogenic compounds—molecules that inhibit the growth of vessels inside a tumor—together with antineoplastic drugs in order to sensitize the resistant

New Targeting in The Reversal of Resistant Glioblastomas

New Targeting in The Reversal of Resistant Glioblastomas
  • Author : Ali Syed Arbab
  • Publisher : Academic Press
  • Release Date : 2021-03-05
  • ISBN : 9780128232767
GET THIS BOOKNew Targeting in The Reversal of Resistant Glioblastomas

New Targeting in The Reversal of Resistant Glioblastomas discusses alternative treatment strategies that not only target tumor cells but also target the tumor microenvironment, metabolic pathways and interaction of cytokines in tumor cells. The current treatment for primary and recurrent glioblastomas is failing because clinicians are not considering the effect of bone marrow derived cells to the development of resistance to clinically practiced therapies. This book helps readers rethink treatment strategies to successfully fight glioblastomas. It is a valuable resource

Biotargets of Cancer in Current Clinical Practice

Biotargets of Cancer in Current Clinical Practice
  • Author : Mauro Bologna
  • Publisher : Springer Science & Business Media
  • Release Date : 2012-04-05
  • ISBN : 9781617796142
GET THIS BOOKBiotargets of Cancer in Current Clinical Practice

Biotargets of Cancer in Current Clinical Practice presents an updated and reasoned review of the current status of knowledge concerning the major cancer types with a special focus on the current biomarkers, genes involved and the potential future targets of innovative therapies. The volume includes for each major cancer type, a comprehensive although concise discussion of epidemiology, affirmed and innovative biomarkers for diagnosis, and descriptions of the relevant genes for prognosis and (individualized) therapy through biotarget-specific new molecular treatments, with

Third Generation EGFR Inhibitors

Third Generation EGFR Inhibitors
  • Author : Harun M. Patel,Rahul Pawara,Sanjay J. Surana
  • Publisher : Elsevier
  • Release Date : 2018-11-27
  • ISBN : 9780081026625
GET THIS BOOKThird Generation EGFR Inhibitors

Third Generation EGFR Inhibitors: Overcoming EGFR Resistance and Toxicity Problems reviews current issues relating to the design of reversible and irreversible third generation EGFR inhibitors, highlighting the types of mutation responsible for resistance, and providing different chemical starting points for researchers to optimize and develop in designing the next generation of drugs. Beginning with an introduction to EGFR inhibitors and a review of inhibitors currently approved or in clinical trials, the book goes on to discuss current approaches in the

Textbook of Personalized Medicine

Textbook of Personalized Medicine
  • Author : Kewal K. Jain
  • Publisher : Humana Press
  • Release Date : 2015-03-17
  • ISBN : 9781493925537
GET THIS BOOKTextbook of Personalized Medicine

Advances in the technology used in personalized medicine and increased applications for clinical use have created a need for this expansion and revision of Kewal K. Jain’s Textbook of Personalized Medicine. As the first definitive work on this topic, this book reviews the fundamentals and development of personalized medicine and subsequent adoptions of the concepts by the biopharmaceutical industry and the medical profession. It also discusses examples of applications in key therapeutic areas, as well as ethical and regulatory

Lung Cancer and Personalized Medicine: Novel Therapies and Clinical Management

Lung Cancer and Personalized Medicine: Novel Therapies and Clinical Management
  • Author : Aamir Ahmad,Shirish M. Gadgeel
  • Publisher : Springer
  • Release Date : 2015-12-24
  • ISBN : 9783319249322
GET THIS BOOKLung Cancer and Personalized Medicine: Novel Therapies and Clinical Management

This, the second of two volumes on personalized medicine in lung cancer, touches upon the recent progress in targeted drug development based on genomics; emerging biomarkers and therapeutic targets such as EMT, cancer stem cells, and the tumor microenvironment; current personalized clinical management and radiation therapy for lung cancers; and the promise of epigenetics and next-generation sequencing for the advancements towards personalized therapy of lung cancer patients. With chapters on state-of-the-art therapies and technologies written by leading experts working to

Novel Small-Molecule Agents in Overcoming Multidrug Resistance in Cancers

Novel Small-Molecule Agents in Overcoming Multidrug Resistance in Cancers
  • Author : Qingbin Cui,Yingfang Fan,Qianxiong Zhou,Cong Wang,Leli Zeng
  • Publisher : Frontiers Media SA
  • Release Date : 2022-05-30
  • ISBN : 9782889762354
GET THIS BOOKNovel Small-Molecule Agents in Overcoming Multidrug Resistance in Cancers

AACR 2016: Abstracts 1-2696

AACR 2016: Abstracts 1-2696
  • Author : American Association for Cancer Research (AACR)
  • Publisher : CTI Meeting Technology
  • Release Date : 2016-03-28
  • ISBN : 0987654321XXX
GET THIS BOOKAACR 2016: Abstracts 1-2696

The AACR Annual Meeting is a must-attend event for cancer researchers and the broader cancer community. This year's theme, "Delivering Cures Through Cancer Science," reinforces the inextricable link between research and advances in patient care. The theme will be evident throughout the meeting as the latest, most exciting discoveries are presented in every area of cancer research. There will be a number of presentations that include exciting new data from cutting-edge clinical trials as well as companion presentations that spotlight